Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Miptenalimab |
Trade Name | |
Synonyms | BI 754111|BI754111|BI-754111 |
Drug Descriptions |
Miptenalimab (BI 754111) is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4547). |
DrugClasses | Immune Checkpoint Inhibitor 149 LAG3 Antibody 18 |
CAS Registry Number | 2245092-03-7 |
NCIT ID | C150403 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BI 907828 + Ezabenlimab + Miptenalimab | BI 907828 Ezabenlimab Miptenalimab | 0 | 1 |
Ezabenlimab + Miptenalimab | Ezabenlimab Miptenalimab | 0 | 0 |
Miptenalimab | Miptenalimab | 0 | 2 |